Skip to navigation Skip to content

Hodgkin lymphoma (HL) Program in Pharmaceutical Benefits Scheme (PBS) 012-18042700

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma (HL) and who have failed autologous stem cell transplant (ASCT) or are ASCT naïve.

HL and listing dates

HL is a cancer of the immune system.

Listing dates:

  • brentuximab vedotin- 1 April 2017
  • pembrolizumab - 1 May 2018

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia website.

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing Written Authority requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Work Optimiser for staff

Written Authority Required Drugs